Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure

Table 2 Clinical features of acute-on-chronic liver failure patients based on different outcomes

Features	Spontaneous recovery (n = 33)	Non spontaneous recovery (n = 48)	P value
Age (yr)	41.06 ± 12.48	44.06 ± 10.04	0.235
Male	29 (87.88)	38 (79.17)	0.308
HBV DNA viral load (Log)	5.78 ± 1.62	5.29 ± 2.31	0.487
ALT (U/L)	540.98 ± 555.99	525.15 ± 920.58	0.098
AST (U/L)	412.38 ± 525.00	397.69 ± 605.02	0.645
Total bilirubin (μmol/L)	371.38 ± 199.37	407.99 ± 211.36	0.435
Albumin (g/L)	31.67 ± 3.58	30.82 ± 4.24	0.492
Crea (μmol/L)	68.20 ± 31.59	88.34 ± 59.38	0.094
Prothrombin activity	35.89% ± 10.62%	28.45% ± 10.73%	0.003
International normalized ratio	2.04 ± 0.49	2.67 ± 1.18	0.003
White blood cell (× 109/L)	8.40 ± 3.66	8.20 ± 4.10	0.571
Platelet (× 1012/L)	119.44 ± 51.17	95.60 ± 61.65	0.017
M30 (U/L)	891.35 ± 741.27	695.24 ± 385.15	0.663
M65 (U/L)	2477.23 ± 1671.10	2497.77 ± 1503.84	0.488
M30/M65	0.38 ± 0.13	0.32 ± 0.10	0.032
MELD score	23.07 ± 4.89	27.59 ± 6.55	0.002
Child-Pugh score	11.42 ± 1.23	12.49 ± 1.14	0.000

Data are presented as numbers (percentage) or mean ± SD. HBV: Hepatitis B virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; MELD: Model for End-Stage Liver Disease.